Ondine Biomedical (LON:OBI) Trading Down 7.9% – Should You Sell?

Ondine Biomedical Inc. (LON:OBI) dropped 7.9% on Tuesday . The company traded as low as C$12.00 and last traded at C$12.25. Approximately 53,936 shares were traded during mid-day trading, a decline of 87% from the average daily volume of 429,282 shares. The stock had previously closed at C$13.30.

Ondine Biomedical Price Performance

The company has a fifty day moving average of C$9.73 and a 200-day moving average of C$8.16. The company has a current ratio of 0.80, a quick ratio of 8.26 and a debt-to-equity ratio of 1,847.37. The stock has a market cap of C$3.40 billion, a PE ratio of -408.33 and a beta of 0.10.

Insiders Place Their Bets

In other news, insider Carolyn Cross purchased 149,225 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The stock was bought at an average price of C$13.00 per share, for a total transaction of C$1,939,925.00. Insiders own 36.69% of the company’s stock.

About Ondine Biomedical

Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens.

Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings.